相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer
Aurelia Noske et al.
HISTOPATHOLOGY (2021)
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
Tess A. O’Meara et al.
Oncotarget (2021)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Katherine E. Hutchinson et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
Guoxuan Gao et al.
BMC CANCER (2020)
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
Nina Ditsch et al.
BREAST CARE (2020)
Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130
Hope Rugo et al.
CANCER RESEARCH (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
Quirine F. Manson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2019)
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
Markus Eckstein et al.
EUROPEAN JOURNAL OF CANCER (2019)
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy
David J. Zahavi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression
Ju-Ha Kim et al.
MOLECULAR CANCER (2019)
Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogens and Its Receptors Into Cancer Physiopathology
Mariana Segovia-Mendoza et al.
FRONTIERS IN IMMUNOLOGY (2019)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)
S Adams et al.
CANCER RESEARCH (2018)
Hypermutated Tumors and Immune Checkpoint Inhibition
Kristen K. Ciombor et al.
DRUGS (2018)
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells
Ossama Tawfik et al.
HUMAN PATHOLOGY (2018)
PD-L1 in breast cancer: comparative analysis of 3 different antibodies
Tejashree Karnik et al.
HUMAN PATHOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
Enrico Munari et al.
Oncotarget (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness et al.
ANNALS OF ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
Vamsidhar Velcheti et al.
PLOS ONE (2018)
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
Wendie D. den Brok et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Hironori Uruga et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Carlos R. Gil Del Alcazar et al.
CANCER DISCOVERY (2017)
Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology
Neelima Vidula et al.
ONCOTARGET (2017)
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
Hitomi Mori et al.
ONCOTARGET (2017)
First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases
Manal Elidrissi Errahhali et al.
BMC WOMENS HEALTH (2017)
Breast tumor stroma: A driving force in the development of resistance to therapies
Maryam Majidinia et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
Jacquelyn Smith et al.
DIAGNOSTIC PATHOLOGY (2016)
Validation of an electronic program for pathologist training in the interpretation of a complex companion diagnostic immu-nohistochemical assay
Eslie Dennis et al.
HUMAN PATHOLOGY (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista et al.
HUMAN PATHOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome
Marius Ilie et al.
MODERN PATHOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Programmed Death-Ligand 1 (PD-L1) immumohistochemistry in NSCLC: Comparison and correlation between two antibodies.
Gareth Rivalland et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Complementary versus companion diagnostics: apples and oranges?
Christopher-Paul Milne et al.
BIOMARKERS IN MEDICINE (2015)
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
Leisha A. Emens et al.
CANCER RESEARCH (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Marta Bonotto et al.
ONCOLOGIST (2014)
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Hatem Soliman et al.
PLOS ONE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L. Malorni et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
FOXP3+ Tregs and B7-HI+/PD-I+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients:: Implication for immunotherapy
Hazem Ghebeh et al.
BMC CANCER (2008)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
分享论文
